Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

被引：2
|
作者：
El Melegy, N. T. [1 ]
Aboulella, H. A. [2 ]
Abul-Fadl, A. M. [1 ]
Mohamed, N. A. [1 ]
机构：
[1] Assiut Univ, Fac Med, Dept Biochem, Assiut, Egypt
[2] Assiut Univ, Fac Med, Dept Urol, Assiut, Egypt
来源：
BRITISH JOURNAL OF BIOMEDICAL SCIENCE | 2010年 / 67卷 / 03期
关键词：
N-Acetylneuraminic acid; Prostate-specific antigen; Prostatic hyperplasia; Prostatic neoplasms; SERUM SIALIC-ACID; CATHEPSIN-D; ANTIGEN RATIO; MEN; DIAGNOSIS; MARKER; LEVEL; AGE;
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
This study aims to evaluate the role of free/total prostate-specific antigen (PSA) ratio, serum total sialic acid level and cathepsin D activity in the differentiation of prostate cancer and benign prostatic hyperplasia (BPH). The study looked at 100 patients with BPH, 75 patients with organ-confined or locally advanced prostate cancer, and a control group of 50 healthy volunteers. Prostate cancer patients showed significantly higher total sialic acid level and cathepsin D activity and lower free/total PSA ratio than those in the BPH group. The results suggest that combined measurement of serum total sialic acid and/or cathepsin D activity with free/total PSA ratio could serve as a useful adjunct to conventional diagnostics for the differentiation of prostate cancer and BPH.
引用
下载
收藏
页码：109 / 112
页数：4
相关论文
共 50 条
  • [1] Fibromodulin Gene Variants (FMOD) as Potential Biomarkers for Prostate Cancer and Benign Prostatic Hyperplasia
    Silva, Tamara
    Gomes, Caroliny Pinto
    Voigt, Danielle Dutra
    de Souza, Ritiele Bastos
    Medeiros, Karoline
    Cosentino, Nicole Lima
    Fonseca, Ana Carolina Proenca
    Tilli, Tatiana Martins
    Loayza, Enrique Antonio Covarrubias
    Ramos, Vivianne Galante
    Acero, Pedro Hernan Cabello
    DISEASE MARKERS, 2022, 2022
  • [2] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (01): : F20 - F22
  • [3] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
  • [4] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [5] Benign prostatic hyperplasia and prostate cancer
    Guess, HA
    EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) : 152 - 158
  • [6] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    BYAR, DP
    LANCET, 1975, 1 (7911): : 866 - 866
  • [7] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42
  • [8] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (01): : F18 - F20
  • [9] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    WILLIAMS, RD
    BLACKARD, CE
    LANCET, 1974, 2 (7891): : 1265 - 1265
  • [10] Benign prostatic Hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (03): : F65 - F66
12345